

Caitriona Ryan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8098253/publications.pdf>

Version: 2024-02-01

60
papers

3,588
citations

172207

29
h-index

143772

57
g-index

63
all docs

63
docs citations

63
times ranked

4199
citing authors

#	ARTICLE	IF	CITATIONS
1	The impact of achieving and maintaining near-complete or complete skin clearance on patient quality of life in moderate-to-severe psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2023, 88, 169-172.	0.6	5
2	Ixekizumab provides persistent improvements in health-related quality of life and the sexual impact associated with moderate-to-severe genital psoriasis in adult patients during a 52-week, randomised, placebo-controlled, phase 3 clinical trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	1.3	1
3	Psoriasis severity: commonly used clinical thresholds may not adequately convey patient impact. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 417-421.	1.3	11
4	Obstructive sleep apnoea in psoriasis and hidradenitis suppurativa. <i>British Journal of Dermatology</i> , 2021, 184, 1183-1185.	1.4	6
5	High Levels of Psychological Distress, Sleep Disturbance, and Alcohol Use Disorder in Adults With Atopic Dermatitis. <i>Dermatitis</i> , 2021, 32, S33-S38.	0.8	6
6	Ixekizumab. , 2021, , 253-262.		0
7	Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 117-122.	0.6	120
8	Ixekizumab Results in Persistent Clinical Improvement in Moderate-to-Severe Genital Psoriasis During a 52 Week, Randomized, Placebo-Controlled, Phase 3 Clinical Trial. <i>Acta Dermato-Venereologica</i> , 2020, 100, 1-9.	0.6	22
9	Genital Psoriasis: Impact on Quality of Life and Treatment Options. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 639-646.	3.3	16
10	Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. <i>Lancet, The</i> , 2019, 394, 576-586.	6.3	198
11	Genital psoriasis: the failure of dermatologists to identify genital involvement. <i>British Journal of Dermatology</i> , 2019, 180, 460-461.	1.4	11
12	Clinical considerations for the management of psoriasis in women. <i>International Journal of Women's Dermatology</i> , 2019, 5, 141-150.	1.1	44
13	Biosimilars for Psoriasis—Experience from Europe. <i>Current Dermatology Reports</i> , 2019, 8, 26-34.	1.1	6
14	Clinical Goals and Barriers to Effective Psoriasis Care. <i>Dermatology and Therapy</i> , 2019, 9, 5-18.	1.4	63
15	Adalimumab treatment for psoriasis — safety in numbers. <i>British Journal of Dermatology</i> , 2019, 180, 14-15.	1.4	0
16	Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 437-447.	3.3	26
17	The Development of the Genital Psoriasis Sexual Frequency Questionnaire (GenPs-SFQ) to Assess the Impact of Genital Psoriasis on Sexual Health. <i>Dermatology and Therapy</i> , 2018, 8, 33-44.	1.4	14
18	The Development of a Patient-Reported Outcome Measure for Assessment of Genital Psoriasis Symptoms: The Genital Psoriasis Symptoms Scale (GPSS). <i>Dermatology and Therapy</i> , 2018, 8, 45-56.	1.4	21

#	ARTICLE	IF	CITATIONS
19	Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 383-394.	0.6	69
20	Ixekizumab Improved Patient-Reported Genital Psoriasis Symptoms and Impact of Symptoms on Sexual Activity vs Placebo in a Randomized, Double-Blind Study. <i>Journal of Sexual Medicine</i> , 2018, 15, 1645-1652.	0.3	34
21	Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis. <i>British Journal of Dermatology</i> , 2018, 179, 844-852.	1.4	87
22	From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 290-298.	0.6	137
23	Identification of pharmacogenetic markers of treatment response to biologic therapies in psoriasis - is there a benefit?. <i>British Journal of Dermatology</i> , 2017, 176, 1127-1128.	1.4	1
24	Patients' Perspectives on the Impact of Genital Psoriasis: A Qualitative Study. <i>Dermatology and Therapy</i> , 2017, 7, 447-461.	1.4	39
25	Infection-free Clinical Response Among Patients With Hidradenitis Suppurativa Who Were Treated With Adalimumab: Results from Two Phase 3 Studies. <i>Wounds</i> , 2017, 29, E98-E102.	0.2	4
26	Disseminated Cutaneous Histoplasmosis in Newly Diagnosed Hiv. <i>Baylor University Medical Center Proceedings</i> , 2016, 29, 50-51.	0.2	4
27	Developing more open and equitable relationships with industry to improve advancements in clinical research in dermatology. <i>British Journal of Dermatology</i> , 2016, 174, 1365-1369.	1.4	4
28	Discordance between physician assessment of psoriasis and patient self-assessment: the importance of itch. <i>British Journal of Dermatology</i> , 2016, 175, 19-20.	1.4	5
29	Comparison of Coronary Artery Calcium Scores Between Patients With Psoriasis and Type 2 Diabetes. <i>JAMA Dermatology</i> , 2016, 152, 1244.	2.0	56
30	Genital psoriasis is associated with significant impairment in quality of life and sexual functioning. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 978-983.	0.6	155
31	An overview of developing TNF- α targeted therapy for the treatment of psoriasis. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1343-1354.	1.9	27
32	Psoriasis Is a Systemic Disease with Multiple Cardiovascular and Metabolic Comorbidities. <i>Dermatologic Clinics</i> , 2015, 33, 41-55.	1.0	138
33	The prevalence of Dupuytren contractures in patients with psoriasis. <i>Clinical and Experimental Dermatology</i> , 2014, 39, 894-899.	0.6	6
34	Ponesimodine: a future oral therapy for psoriasis?. <i>Lancet, The</i> , 2014, 384, 2006-2008.	6.3	10
35	Research gaps in psoriasis: Opportunities for future studies. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 146-167.	0.6	101
36	Genetic markers of treatment response to tumour necrosis factor- α inhibitors in the treatment of psoriasis. <i>Clinical and Experimental Dermatology</i> , 2014, 39, 519-524.	0.6	34

#	ARTICLE	IF	CITATIONS
37	The use of tumor necrosis factor inhibitors in pregnancy: What is the evidence?. Journal of the American Academy of Dermatology, 2014, 71, 829-831.	0.6	1
38	Novel Sodium Hypochlorite Cleanser Shows Clinical Response and Excellent Acceptability in the Treatment of Atopic Dermatitis. Pediatric Dermatology, 2013, 30, 308-315.	0.5	54
39	Levamisole-Induced Vasculitis. Baylor University Medical Center Proceedings, 2013, 26, 163-165.	0.2	31
40	Psoriatic Arthritis: An Update. Arthritis, 2012, 2012, 1-6.	2.0	41
41	Current investigational drugs in psoriasis. Expert Opinion on Investigational Drugs, 2012, 21, 473-487.	1.9	33
42	A Subset of Methylated CpG Sites Differentiate Psoriatic from Normal Skin. Journal of Investigative Dermatology, 2012, 132, 583-592.	0.3	138
43	Flow Cytometry. Journal of Investigative Dermatology, 2012, 132, 1-6.	0.3	63
44	PSORS2 Is Due to Mutations in CARD14. American Journal of Human Genetics, 2012, 90, 784-795.	2.6	365
45	Psoriasis and cardiovascular disorders. Giornale Italiano Di Dermatologia E Venereologia, 2012, 147, 179-87.	0.8	12
46	Deep sequencing of small RNAs from human skin reveals major alterations in the psoriasis miRNAome. Human Molecular Genetics, 2011, 20, 4025-4040.	1.4	213
47	Cytomegalovirus-induced cutaneous vasculopathy and perianal ulceration. Journal of the American Academy of Dermatology, 2011, 64, 1216-1218.	0.6	16
48	Guidelines of care for the management of psoriasis and psoriatic arthritis. Journal of the American Academy of Dermatology, 2011, 65, 137-174.	0.6	398
49	Use of pharmacogenomics in psoriasis. Clinical Investigation, 2011, 1, 399-411.	0.0	4
50	Complete skin examination is essential in the assessment of dermatology patients: findings from 483 patients. British Journal of Dermatology, 2011, 165, 1124-1126.	1.4	6
51	Association Between Biologic Therapies for Chronic Plaque Psoriasis and Cardiovascular Events. JAMA - Journal of the American Medical Association, 2011, 306, 864-71.	3.8	259
52	Clinical and genetic predictors of response to narrowband ultraviolet B for the treatment of chronic plaque psoriasis. British Journal of Dermatology, 2010, 163, 1056-1063.	1.4	33
53	The use of ustekinumab in autoimmune disease. Expert Opinion on Biological Therapy, 2010, 10, 587-604.	1.4	44
54	The Effect of Narrowband UV-B Treatment for Psoriasis on Vitamin D Status During Wintertime in Ireland. Archives of Dermatology, 2010, 146, 836-42.	1.7	55

#	ARTICLE	IF	CITATIONS
55	The use of cyclosporine in dermatology: Part II. Journal of the American Academy of Dermatology, 2010, 63, 949-972.	0.6	117
56	The use of cyclosporine in dermatology: Part I. Journal of the American Academy of Dermatology, 2010, 63, 925-946.	0.6	136
57	The Latest Advances in Pharmacogenetics and Pharmacogenomics in the Treatment of Psoriasis. Molecular Diagnosis and Therapy, 2010, 14, 81-93.	1.6	29
58	Treatment of acrodermatitis continua of Hallopeau with adalimumab. British Journal of Dermatology, 2009, 160, 203-205.	1.4	26
59	Juvenile folliculotropic and ichthyosiform mycosis fungoides. Clinical and Experimental Dermatology, 2009, 34, e160-e162.	0.6	7
60	Adalimumab treatment for severe recalcitrant chronic plaque psoriasis. Clinical and Experimental Dermatology, 2009, 34, 784-788.	0.6	26